Curated CRC research, accessible, accurate, actionable

The CRC Digest

Thursday, October 08, 2026

Was this forwarded to you? Read on the web or subscribe free

IMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.

CRC Research Update

• ◇ RESEARCH

  KRAS G12C inhibitors show clinical success, but resistance and co-mutation context limit durable benefit

  A review of KRAS-mutant cancers notes that covalent KRAS G12C inhibitors have transformed a historically "undruggable" target into a tractable therapeutic class, though durable benefit remains limited by adaptive feedback, acquired resistance, and tumor-lineage-specific barriers. (MedComm)

• ◆ TRIAL DATA

  Mitomycin C HIPEC after cytoreductive surgery shows unclear oncologic benefit in colorectal peritoneal metastases

  A propensity score-matched analysis compared patients who received mitomycin C-based hyperthermic intraperitoneal chemotherapy after complete cytoreductive surgery (2009–2021) with those undergoing surgery alone (2021–2024), following the PRODIGE7 trial's finding that oxaliplatin-based HIPEC lacked effectiveness. (Ann Surg Oncol)

• ▪ SCREENING

  Nurse endoscopists maintain high technical quality in Sweden's nationwide colorectal cancer screening program

  An observational study evaluated nurse endoscopists' performance in Sweden's nationwide screening program for individuals aged 60-74 (which started in 2021) on core quality indicators, adenoma detection rate, cecal and ileal intubation rates, bowel preparation, sedation use, and complications, compared with physician endoscopists. (Endoscopy)

• ◇ RESEARCH

  Pan-cancer study in India finds 24.9% of tumors are MSI-high or MMR-deficient, with 51.2% harboring pathogenic germline variants

  A tumor-first approach applied to 519 patients with colorectal and extracolonic cancers from 17 centers in India (2019–2025) identified MSI-high or MMR-deficient status in 24.9% of tumors, and 51.2% of those patients harbored pathogenic or likely pathogenic germline variants. (Fam Cancer)

This week's research spans biomarker discovery, screening quality assurance, and the evolving landscape of targeted therapy for KRAS-mutant disease.